Novo Nordisk’s Pipeline Progress Collides With a Darkening Revenue Outlook
Novo Nordisk balances rare-disease wins and obesity pipeline data against a grim 2026 revenue forecast and rising competition…
Teen Pill Success Meets Canadian Generic Shock
Novo Nordisk celebrates positive trial results for oral semaglutide in teens while facing first generic Ozempic competition in…
Novo Nordisk’s Hemophilia Breakthrough Fails to Distract From Canadian Generic Blow
Novo Nordisk’s stock slides 41% as Canada approves first generic Ozempic, while promising hemophilia data fails to lift…
Novo Nordisk’s Oral Wegovy Pill Surges Past Eli Lilly, but Generics and Price Pressure Loom
Novo Nordisk’s oral Wegovy pill leads Eli Lilly’s Foundayo 2-to-1 in US prescriptions, but faces generic competition in…
Novo Nordisk’s Teen Trial Victory Can’t Mask the Storm Brewing in Canada
Novo Nordisk faces a mixed outlook: FDA approves oral Ozempic for teens, but Canadian generics and US price…
Novo Nordisk’s Teen Pill Breakthrough and Canadian Generic Blow Arrive in the Same Week
Novo Nordisk faces a historic Ozempic generic in Canada while scoring a first-in-class oral GLP-1 win for teens,…
Novo Nordisk’s Teen Trial Win Offers a Glimmer as US Price War Bites
Novo Nordisk’s oral semaglutide shows breakthrough in teens with type 2 diabetes, but US pricing squeeze and Eli…
Novo Nordisk’s Buyback Blitz and FDA Fast-Track Mask a Steep Profit Slide
Novo Nordisk spends billions on share repurchases but faces a 50% stock drop, 2026 revenue decline, and fierce…
Novo Nordisk’s Chinese Patent Shield and Teen Trial Win Create a Two-Fronted Story
Novo Nordisk faces a paradox: Chinese regulatory delays protect $1B semaglutide sales, while oral semaglutide targets teens and…
Novo Nordisk’s Pipeline Delivers Two Wins as Stock Sinks to Oversold Territory
Novo Nordisk secures rare disease and pediatric diabetes milestones, but shares fall 21% YTD on GLP-1 competition and…
Novo Nordisk’s CagriSema Data Locked as Pipeline Hopes Wrestle With a 50% Stock Wipeout
Novo Nordisk locks Phase 3 data for CagriSema vs Lilly’s Tirzepatid in diabetes, with shares at half their…
Novo Nordisk’s Oral Pill Crushes Lilly’s Foundayo in Prescription Race, but a 50% Stock Rout Tel
Eli Lilly’s Foundayo trails Novo Nordisk’s oral Wegovy in weekly scripts; Novo faces stock slump but scores pediatric…